Current Clinical Trials

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants.” Clinical Trials FAQs.

Want to Participate In a Clinical Trial?

Consider Participating

There are a lot of important things to think about before deciding to participate. Check out some of the key considerations here.

Participating in a Clinical Trial

Current Clinical Studies

To enroll in a clinical study, check out our list of Clinical Trials and click on the "Recruiting" button for the relevant trial.

Visit Our Trials Site

Completed Trials

Condition	Study Number	Description	Status (click on link to learn more)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	IgPro20_3004	Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Results
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	IgPro10_5004	Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)	Cancelled
Dermatomyositis (DM)	IgPro20_3007	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults with Dermatomyositis (DM) [RECLAIIM]	Cancelled
Primary Immune Deficiency (PID)	IgPro20_1001	Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump	Results Synopsis (PDF)
Primary Immune Deficiency (PID)	IgPro20_4004	Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID)	Results Synopsis (PDF)
Primary Immune Deficiency (PID)	IgPro20_4005	Study of Immune Deficiency Patients Treated with Subcutaneous Immunoglobulin (Hizentra®) on Weekly and Biweekly Schedules	Results Synopsis (PDF)
Systemic Sclerosis	IgPro10_2001	Efficacy and Safety Study of IgPro10 in Adults with Systemic Sclerosis	Withdrawn
Systemic Sclerosis	IgPro20_2001	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of IgPro20 in Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc).	Results

Condition	Study Number	Description	Status (click on link to learn more)
Reversal of acquired coagulation factor deficiency	BE1116_4001	An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra®or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding	Completed
Congenital Fibrinogen Deficiency	BI3023_4003	An Observational Study of the Safety and Efficacy of Fibrinogen Concentrate Human (FCH) in Subjects With Congenital Fibrinogen Deficiency	Completed
Hemophilia A	CSL627_3001	An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A	Results Synopsis-PUP (PDF) Synopsis (PDF)
Hemophilia B	CSL222_2001	Dose Confirmation Trial of AAV5-hFIXco-Padua	Results
Hemophilia B	CSL654_3001	A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B	Results
Hemophilia B	CSL654_3002	A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B	Results Synopsis (PDF)
Hemophilia B	CSL654_3003	A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B	Results
Hemophilia B	CT-AMT-060-01	Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B	Results
Hemophilia B	CSL222_3001	HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients	Results
Hemophilia A or B	CSL689_2001	Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors	Cancelled
Sickle Cell	CSL200_1001	CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease	Cancelled
Sickle Cell	CSL889_1001	Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease	Completed
Traumatic Injury and Acute Major Bleeding	BE1116_3006	Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )	Cancelled
Von Willebrand Disease	CSLCT-BIO-12-83	Study of Voncento® in Subjects With Von Willebrand Disease	Completed
Healthy Volunteers	CSL624_1005	Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults	Completed

Condition	Study Number	Description	Status (click on link to learn more)
Acute Coronary Syndrome	CSL112_3001	Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome	Results
Antibody-mediated kidney transplant rejection	CSL300_3001	A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients [IMAGINE]	Cancelled
Coronary Heart Disease	CSL112_1001	Assessing the Pharmacokinetics, Safety, and Tolerability of CSL112 in Healthy Japanese and Caucasian Adults	Completed
Diabetic Kidney Disease	CSL346_2001	Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease	Results
Hereditary Angioedema	CSL830_3002	A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	Results
Idiopathic Pulmonary Fibrosis	CSL312_2002	Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	Results
Renal Impairment and Acute Myocardial Infarction	CSL112_2001	A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction	Results Synopsis (PDF)
Acute Myocardial Infarction	CSLCT-HDL-12-77	A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.	Results Synopsis (PDF)

Condition	Study Number	Description	Status (click on link to learn more)
Hereditary Angioedema (HAE)	CSL312_2001	A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)	Results
Hereditary Angioedema (HAE)	CSL312_3001	CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks	Results
Hereditary Angioedema (HAE)	CSL830_2001	A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route	Results Synopsis (PDF)
Hereditary Angioedema (HAE)	CSL830_3001	A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	Results Synopsis (PDF)
Hereditary Angioedema (HAE)	CSL830_3002	A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	Results Synopsis (PDF)
Hereditary Angioedema (HAE)	CSL830_3003	A Phase 3 Study to Evaluate Clinical Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Human Plasma Derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema in Japanese Subjects	Results Synopsis (PDF)
Hidradenitis Suppurativa and Palmoplantar Pustulosis	CSL324_1002	Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis	Completed
HIV-1	CAL-USA-11	An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART	Results Synopsis (PDF)
Healthy Subjects	CSL312_1003	A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults	Completed
Healthy Subjects	CSL312_3004	A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects	Completed
Healthy Subjects	CSL324_1001	Dose Escalation, Placebo-controlled Phase 1 Study to Assess the Safety and Tolerability of CSL324 in Healthy Adults	Completed
Healthy Subjects	CSL324_1003	Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects	Completed
Healthy Subjects	CSL324_1004	Effects of CSL324 in the Lung After Segmental Challenge	Completed
Healthy Subjects	CSL730_1001	Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults	Cancelled
Healthy Subjects	CSL730_1002	Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects	Cancelled
PICC-associated Thrombosis	CSL312_1002	A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line	Withdrawn
Antibody-mediated kidney transplant rejection	CSL842_3001	Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR)in Adult Renal Transplant Recipients	Results

Condition	Study Number	Description	Status (click on link to learn more)
Condition	Study Number	Description	Status (click on link to learn more)
COVID-19	CSL312_COVID-19	A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)	Results
COVID-19	CSL324_COVID-19	CSL324 in COVID-19	Withdrawn
COVID-19	CSL760_1001	Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects	Cancelled